Abstract

BackgroundThe aim of this study was to detect CMY-type beta-lactamases in E. coli isolates obtained from paediatric patients.MethodsIn total, 404 infection-causing E. coli isolates resistant to third and fourth generation cephalosporins (3GC, 4GC) were collected from paediatric patients over a 2 years period. The identification and susceptibility profiles were determined with an automated microbiology system. Typing of blaCMY and other beta-lactamase genes (blaTEM, blaSHV, blaCTX-M, blaVIM, blaIMP, blaKPC, blaNDM, blaOXA and blaGES) was realized by PCR and sequencing. Phenotypic detection of AmpC-type enzymes was performed using boronic acid (20 mg/mL) and cloxacillin (20 mg/mL) as inhibitors, and the production of extended-spectrum beta-lactamases was determined with the double-disk diffusion test with cefotaxime (CTX) and ceftazidime (CAZ) discs alone and in combination with clavulanic acid. The CarbaNP test and modified carbapenem inhibition method (mCIM) were used for isolates with decreased susceptibility to carbapenems. The clonal origin of the isolates was established by pulsed-field gel electrophoresis (PFGE), phylotyping method and multilocus sequence typing.ResultsCMY-type beta-lactamases were detected in 18 isolates (4.5%). The allelic variants found were CMY-2 (n = 14) and CMY-42 (n = 4). Of the E. coli strains with CMY, the AmpC phenotypic production test was positive in 11 isolates with cloxacillin and in 15 with boronic acid. ESBL production was detected in 13 isolates. Coexistence with other beta-lactamases was observed such as CTX-M-15 ESBL and original spectrum beta-lactamases TEM-1 and TEM-190. In one isolate, the CarbaNP test was negative, the mCIM was positive, and OXA-48 carbapenemase was detected. Phylogroup A was the most frequent (n = 9) followed by B2, E and F (n = 2, respectively), and through PFGE, no clonal relationship was observed. Eleven different sequence types (ST) were found, with ST10 high-risk clone being the most frequent (n = 4). Seventy-two percent of the isolates were from health care-associated infections; the mortality rate was 11.1%.ConclusionsThis is the first report in Mexico of E. coli producing CMY isolated from paediatric patients, demonstrating a frequency of 4.5%. In addition, this is the first finding of E. coli ST10 with CMY-2 and OXA-48.

Highlights

  • The aim of this study was to detect CMY-type beta-lactamases in E. coli isolates obtained from paediat‐ ric patients

  • In 2014, as part of the International Network for Optimal Resistance Monitoring (INFORM) program, 2,813 E. coli isolates were collected in 69 hospital centres in the USA, and CMY-2 was reported in 74 isolates (2.6%) [10]

  • In 15 isolates, coexistence with other beta-lactamase genes was observed such as CTX-M-15 Extended-spectrum beta-lactamases (ESBL), TEM-1 and TEM-190 Original spectrum beta-lac‐ tamases (OSBL) and OXA-48 carbapenemase

Read more

Summary

Introduction

The aim of this study was to detect CMY-type beta-lactamases in E. coli isolates obtained from paediat‐ ric patients. AmpC types are present in the chromosome of some enterobacteria but can pass to mobile genetic elements, such as plasmids, and be transferred horizontally between different species These enzymes confer resistance to oxyimino-cephalosporins (ceftazidime, cefotaxime), cephamycins (cefoxitin) and monobactams (aztreonam). Eight families of plasmid AmpC have been described based on differences in the amino acid sequence: CMY (cephamycin), FOX (cefoxitin), ACC (Ambler class C), LAT (latamoxef ), MIR (Miriam hospital in Providence), ACT (AmpC type), MOX (moxalactam), and DHA (Dhahran hospital in Saudi Arabia) [3, 5] Of these groups, CMY-2 is the most common type in E. coli and has been reported in Asia, Europe and North America [6,7,8,9]. There is no information on the molecular or epidemiological characteristics of E. coli isolates producing CMY-type beta-lactamases in the Mexican paediatric population

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call